AR074776A1 - Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente - Google Patents
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del pacienteInfo
- Publication number
- AR074776A1 AR074776A1 ARP090104945A ARP090104945A AR074776A1 AR 074776 A1 AR074776 A1 AR 074776A1 AR P090104945 A ARP090104945 A AR P090104945A AR P090104945 A ARP090104945 A AR P090104945A AR 074776 A1 AR074776 A1 AR 074776A1
- Authority
- AR
- Argentina
- Prior art keywords
- patient
- cell
- methyl
- macular degeneration
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente memoria se proporcionan métodos para prevenir, tratar o aliviar una degeneración macular tal como degeneración macular seca, degeneración macular húmeda y degeneración macular asociada a la edad en un paciente. Reivindicación 1: Un método para prevenir, tratar o aliviar la neovascularización coroidal en un paciente, que comprende administrar al paciente una cantidad eficaz de un compuesto que modula el sistema inmunitario del paciente, en donde el sistema inmunitario tiene respuestas inmunes de tipo I y respuestas inmunes de tipo II, de tal modo que administrar el compuesto al paciente aumenta las respuestas inmunes de tipo I en el paciente comparado con las respuestas inmunes de tipo I en el paciente antes de la administración del compuesto. Reivindicación 2: El método de la reivindicación 1, en el que el compuesto se selecciona del grupo que consiste en: (a) un inhibidor de la multicinasa syk; (b) un inhibidor de hPGDS; y (c) un antagonista de DP. Reivindicación 3: El método de la reivindicación 2, en el que el inhibidor de la multicinasa syk se selecciona del grupo que consiste en éster mono-{6-[5-fluoro-2-(3,4,5-trimetoxi-fenilamino)-pirimidin-4-ilamino)-2,2-dimetil-3-oxo-2,3-dihidro-pirido[3,2-b][1,4]oxazin-4-ilmetílico} del ácido fosfórico, sal de ácido acético de fórmula (1) y 2-[4-(7-etil-5H-pirrolo[2,3-b]pirazin-6-il-fenil]-propan-2-ol de fórmula (2). Reivindicación 4: El método de la reivindicación 2, en el que el inhibidor de hPGDS se selecciona del grupo que consiste en: indol-1-ilamida del ácido 2-(3-fluoro-fenil)-4-metil-pirimidina-5-carboxílico de fórmula (3); 3-[5-(1-hidroxi-1-metil-etil)-1,2,4-oxadiazol-3-il]-bencilamida del ácido 2-piridin-2-il-pirimidina-5-carboxílico de fórmula (4); y (5-fluoro-3-metil-indol-1-il)amida del ácido 4-metil-2-piridin-2-il-pirimidina-5-carboxílico de fórmula (5). Reivindicación 5: El método de la reivindicación 2, en el que el antagonista de DP es ácido 2-(3-{6-[2-(2,4-dicloro-fenil)-etilamino]-2-metoxi-pirimidin-4-il}-fenil)-2-metil-propiónico, sal de ácido fosfórico de fórmula (6). Reivindicación 6: El método de cualquiera de las reivindicaciones 1-5, en el que el compuesto modula la actividad de un inmunocito en el paciente. Reivindicación 7: El método de la reivindicación 6, en el que el inmunocito es una célula asesina natural (célula NK), una célula T asesina natural (célula NKT), un mastocito, una célula dendrítica, un granulocito seleccionado del grupo que consiste en un eosinófilo, un basófilo y un neutrófilo, o cualquier combinación de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13870508P | 2008-12-18 | 2008-12-18 | |
FR0955794 | 2009-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR074776A1 true AR074776A1 (es) | 2011-02-09 |
Family
ID=41716610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090104945A AR074776A1 (es) | 2008-12-18 | 2009-12-17 | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
Country Status (15)
Country | Link |
---|---|
US (1) | US20110301125A1 (es) |
EP (2) | EP2653193A1 (es) |
JP (1) | JP2012512895A (es) |
KR (1) | KR20110097955A (es) |
CN (1) | CN102316868A (es) |
AR (1) | AR074776A1 (es) |
AU (1) | AU2009335749A1 (es) |
BR (1) | BRPI0922465A2 (es) |
CA (1) | CA2747478A1 (es) |
IL (1) | IL213550A0 (es) |
MX (1) | MX2011006391A (es) |
SG (2) | SG196770A1 (es) |
TW (1) | TW201034675A (es) |
UY (1) | UY32346A (es) |
WO (1) | WO2010080563A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE531699T1 (de) * | 2007-06-29 | 2011-11-15 | Sanofi Sa | Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4- |
RU2015151129A (ru) * | 2009-10-08 | 2019-01-15 | Санофи | Производные фенилоксадиазола в качестве ингибиторов pgds |
CN105126122A (zh) * | 2014-12-12 | 2015-12-09 | 中国人民解放军第四军医大学 | microRNA mimics用于制备治疗脉络膜新生血管药物的应用 |
CN107519491B (zh) * | 2017-09-04 | 2020-08-25 | 无锡市人民医院 | Copb2抑制剂的用途 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
CH671155A5 (es) | 1986-08-18 | 1989-08-15 | Clinical Technologies Ass | |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
DE69009946T2 (de) | 1989-12-04 | 1994-11-03 | Searle & Co | System zur transdermalen Albuterol Applikation. |
WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
EP0617665B1 (en) | 1991-12-18 | 1999-03-31 | Minnesota Mining And Manufacturing Company | Multilayered barrier structures |
ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US6977283B1 (en) | 1998-04-07 | 2005-12-20 | Exxonmobil Chemical Patents Inc. | Polymerization process |
EP0964361A1 (en) | 1998-06-08 | 1999-12-15 | International Business Machines Corporation | Protection of sensitive information contained in integrated circuit cards |
CA2383572C (en) | 1999-10-21 | 2007-12-11 | Alcon Universal Ltd. | Sub-tenon drug delivery |
US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
US20050059639A1 (en) | 2003-09-11 | 2005-03-17 | Wei Edward T. | Ophthalmic compositions and method for treating eye discomfort and pain |
NZ547689A (en) * | 2003-11-19 | 2009-05-31 | Signal Pharm Llc | Indazole compounds and methods of use thereof as protein kinase inhibitors |
DOP2005000039A (es) | 2004-03-26 | 2005-10-31 | Aventis Pharma Inc | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
US20050234030A1 (en) * | 2004-04-20 | 2005-10-20 | Wilmin Bartolini | Modulators of CRTH2, COX-2 and FAAH |
US20050261243A1 (en) * | 2004-04-21 | 2005-11-24 | Peyman Gholam A | Antiprostaglandins for the treatment of ocular pathologies |
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
WO2007041358A2 (en) * | 2005-09-30 | 2007-04-12 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
CN101316587B (zh) * | 2005-09-30 | 2013-04-03 | 迈卡纳治疗股份有限公司 | 取代的吡唑化合物 |
GT200600457A (es) * | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
AR060403A1 (es) * | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
JP2010506948A (ja) * | 2006-10-20 | 2010-03-04 | アイアールエム・リミテッド・ライアビリティ・カンパニー | C−kitおよびpdgfr受容体を調節するための組成物および方法 |
EP2420505A1 (en) * | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
KR20110009084A (ko) * | 2008-03-10 | 2011-01-27 | 사노피-아벤티스 | 눈-관련된 장애의 치료방법 |
CA2741589A1 (en) * | 2008-11-10 | 2010-05-14 | Pfizer Limited | Pyrrolidines |
-
2009
- 2009-12-17 AR ARP090104945A patent/AR074776A1/es not_active Application Discontinuation
- 2009-12-17 TW TW098143262A patent/TW201034675A/zh unknown
- 2009-12-18 UY UY0001032346A patent/UY32346A/es unknown
- 2009-12-18 US US13/140,799 patent/US20110301125A1/en not_active Abandoned
- 2009-12-18 SG SG2013092796A patent/SG196770A1/en unknown
- 2009-12-18 SG SG2011042868A patent/SG172106A1/en unknown
- 2009-12-18 BR BRPI0922465A patent/BRPI0922465A2/pt not_active Application Discontinuation
- 2009-12-18 EP EP13176594.3A patent/EP2653193A1/en not_active Withdrawn
- 2009-12-18 JP JP2011542460A patent/JP2012512895A/ja active Pending
- 2009-12-18 KR KR1020117016429A patent/KR20110097955A/ko not_active Application Discontinuation
- 2009-12-18 MX MX2011006391A patent/MX2011006391A/es not_active Application Discontinuation
- 2009-12-18 WO PCT/US2009/068625 patent/WO2010080563A2/en active Application Filing
- 2009-12-18 CN CN2009801572927A patent/CN102316868A/zh active Pending
- 2009-12-18 AU AU2009335749A patent/AU2009335749A1/en not_active Abandoned
- 2009-12-18 EP EP09796895A patent/EP2370077A2/en not_active Withdrawn
- 2009-12-18 CA CA2747478A patent/CA2747478A1/en not_active Abandoned
-
2011
- 2011-06-14 IL IL213550A patent/IL213550A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0922465A2 (pt) | 2016-02-10 |
WO2010080563A3 (en) | 2010-08-26 |
TW201034675A (en) | 2010-10-01 |
MX2011006391A (es) | 2011-09-15 |
CA2747478A1 (en) | 2010-07-15 |
KR20110097955A (ko) | 2011-08-31 |
EP2653193A1 (en) | 2013-10-23 |
IL213550A0 (en) | 2011-07-31 |
US20110301125A1 (en) | 2011-12-08 |
EP2370077A2 (en) | 2011-10-05 |
JP2012512895A (ja) | 2012-06-07 |
CN102316868A (zh) | 2012-01-11 |
AU2009335749A1 (en) | 2011-07-07 |
WO2010080563A2 (en) | 2010-07-15 |
SG196770A1 (en) | 2014-02-13 |
SG172106A1 (en) | 2011-07-28 |
UY32346A (es) | 2010-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR120109A1 (es) | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores | |
NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
US9765299B2 (en) | Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells | |
PE20190348A1 (es) | Moduladores de la via de estres integrada | |
CO6612267A2 (es) | Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden | |
NZ605627A (en) | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase | |
EA201001331A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR | |
IN2014DN09221A (es) | ||
ATE496045T1 (de) | Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase | |
MX345830B (es) | Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso. | |
SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
RU2017105781A (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
AR101177A1 (es) | Inhibidores de la syk | |
PE20141023A1 (es) | Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas | |
CO6630133A2 (es) | Compuestos de pirazol -4-il heterociclil -carboxamida y métodos de uso | |
MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
MY163202A (en) | Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof | |
MX348860B (es) | Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa. | |
NZ599815A (en) | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors | |
GT200800105A (es) | Triazolopiridazinas como moduladores de tirosina cinasa | |
WO2013016720A3 (en) | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
ECSP088913A (es) | Derivados de pirimidina tieno [3,2-d] utiles como inhibidores de fi3q | |
MX2013004733A (es) | Inhibidores de n1/n2-lactama acetil-coa carboxilasa. | |
NZ607600A (en) | Compositions for the treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |